Main Line Health
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Main Line Health sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Main Line Health: 3 sponsored US clinical trials, 1 recruiting.
Main Line Health sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pacemaker-Induced Cardiomyopathy, with 1 trials.
Upper-quartile sponsor footprint
Main Line Health sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
NCT06439524
Comparison of Left Bundle Branch Area Versus Right Ventricular Septal Pacing in Patients With High-degree Conduction Disease After Transcatheter Aortic Valve Replacement (Left Bundle BRAVE)
NCT05541679
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy
NCT01727531
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Where Main Line Health enrollment is open (later-stage tilt)
1 recruiting of 3 indexed (33% open); 1 completed (33%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Pacemaker-Induced Cardiomyopathy (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Main Line Health: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Main Line Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Main Line Health page
3 registered trials is a research-attention snapshot, not an endorsement of Main Line Health or any single study.
- 1 of Main Line Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pacemaker-Induced Cardiomyopathy is the condition Main Line Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pacemaker-Induced Cardiomyopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Main Line Health pipeline card: 3 registered trials from official public datasets.Report a data error.